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ABSTRACT
Background: As a consequence of population ageing,
the number of older patients presenting with acute
coronary syndrome (ACS) is increasing. The historical
underrepresentation of older patients in many pivotal
ACS clinical trials undermines the practice of evidence-
based medicine in this high-risk cohort. This study
evaluates the feasibility of recruitment of older patients
to a longitudinal, clinical study.
Methods: The study to Improve Cardiovascular
Outcomes in high-risk patieNts with ACS (ICON-1) is
an observational, prospective cohort study investigating
predictors of poor outcome in older patients with ACS.
All patients aged ≥75 years, referred to a tertiary
cardiovascular centre in the North East of England for
coronary angiography with a view to urgent
percutaneous coronary intervention, were screened for
inclusion. A screening log was prospectively
maintained, and a detailed analysis was performed to
identify the factors associated with recruitment and
non-recruitment to ICON-1.
Results: Of the 629 patients screened over
34 months, 457 (72.7%) satisfied the a priori-defined
study inclusion/exclusion criteria. Of those eligible to
participate, 300 (68.5%) provided informed consent
and were recruited to the study; 59 (13.5%) were
unable to consent due to a lack of capacity or
limitations in communication, and 79 patients (18.0%)
declined to participate in the study. Those lacking
adequate capacity to consent were older than those
able to provide informed consent (83.0±4.7 vs 81.0
±4.7 years, p=0.002). Women were more likely to
decline than men (25.1% vs 10.0%, p<0.001).
Conclusions: The recruitment of patients was robust,
comparing favourably to previous longitudinal studies
within this age group. Although enrolling older people
to research remains challenging, this cohort is
enthusiastic to participate. The contribution of older
patients must not be ignored, particularly in the setting
of an ever-ageing population, in whom cardiovascular
disease burden is high.
Trial registration number: NCT01933581; Pre-results.
INTRODUCTION
Our population is ageing. In England and
Wales, the number of people aged 65 years
or over increased by 1.7 million, from 1985
KEY QUESTIONS
What is already known about this subject?
▸ As a consequence of population ageing, the
number of older patients presenting with acute
coronary syndrome (ACS) is increasing. Despite
the availability of pharmacological and invasive
management options, the landmark studies that
demonstrated the safety and efficacy of these
approaches routinely underrepresented and
excluded older patients, undermining the prac-
tice of evidence-based medicine in this high-risk
cohort. The recruitment of older patients in clin-
ical research is traditionally considered problem-
atic; challenges include (1) increased frequency
of cognitive and sensory impairment, precluding
informed consent, (2) high prevalence of base-
line comorbidity and polypharmacy and (3)
multifactorial loss to follow-up.
What does this study add?
▸ The present study illustrates the feasibility of
including older patients in observational clinical
research in the setting of ACS. The majority of
patients satisfying the study eligibility criteria
were successfully recruited; a minority of patients
lacked capacity to provide informed consent, and
few declined to participate in the study. Women
had a greater tendency to decline to participate
as compared with men, which is reflected in the
lower number of women recruited to the study
overall. The present experience demonstrates that
older patients are generally amenable to consent-
ing to participate in clinical research.
How might this impact on clinical practice?
▸ Older patients have the right to access evidence-
based treatments. Clinical studies must recruit
patients who stand to benefit most from the inter-
vention under investigation. Older patients have a
high burden of cardiovascular disease, are
growing significantly in number and thus may
benefit significantly from novel management
approaches. Future cardiovascular studies should
(1) promote the inclusion of older patients, (2)
aim to recruit a majority of women, (3) consider
the removal of an upper age limit, (4) have access-
ible mechanisms of follow-up and (5) include rele-
vant, age-sensitive outcome measures.
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to 2011.1 Over this period, the fastest increases were
observed in the number over 85, which doubled from
0.7 to 1.4 million.1 Ischaemic heart disease (IHD)
remains the leading cause of death in men and women
over the age of 65 years. National data demonstrate that
49% of all myocardial infarction (MI) occurs in patients
aged over 70 years; 34.2% of all percutaneous coronary
intervention (PCI) procedures are performed in this
group.2 3 Thus, the number of older patients with MI,
presenting to health services and requiring evidence-
based treatment, will increase markedly.
Older patients presenting with acute coronary syn-
drome (ACS) are at higher risk of adverse outcomes;
each 10-year increase in age confers a 75% increase in
in-hospital mortality.4 Despite this well-documented
adverse risk profile, older patients remain significantly
under-represented in clinical cardiovascular studies.
Indeed, 55.2% of randomised controlled trials (RCTs) of
ACS therapies reported between 1996 and 2000 did not
enrol any patients over the age of 75 years; 31.9% actively
excluded patients in this age group.5 The lack of data
regarding the safety and efficacy of interventions in older
patients and particularly those over 85 years undermines
the practice of evidence-based medicine in this high-risk
cohort. However, observational studies of older patients
in other disciplines have shown robust recruitment rates
and a willingness among this age group to actively partici-
pate in medical research.6 Improving the enrolment of
older patients, as well as overcoming the unique chal-
lenges associated with the retention of these patients, is
an imperative priority in clinical cardiology research.
The present study evaluates the recruitment of older
patients to a prospective cohort study, quantifies the
challenges faced during recruitment and identifies the
factors associated with non-participation in order to
provide insights and refine recruitment strategies in
future clinical studies.
METHODS
Study design
The study to Improve Cardiovascular Outcomes in
high-risk patieNts with ACS (ICON-1) is an observa-
tional, prospective cohort study, investigating predictors
of poor outcome in patients aged ≥75 years, under-
going invasive management for non-ST-elevation MI
(NSTEMI) and unstable angina (UA). ICON-1 pro-
spectively recruited patients referred to the Freeman
Hospital in Newcastle upon Tyne, UK, a high-volume
tertiary cardiac centre which performs >3000 PCI pro-
cedures annually.
All patients presenting with ACS, aged ≥75 years and
listed for urgent PCI in the cardiac catheterisation
laboratory were screened by the study team. Study inclu-
sion criteria were (1) age ≥75 years and (2)
non-ST-elevation ACS managed via an invasive approach
(ie, angiography ± PCI). Exclusion criteria comprised
(1) cardiac arrest, ventricular arrhythmia or cardiogenic
shock at presentation or during admission; (2) moderate
or severe valvular disease; (3) malignancy or other life-
limiting comorbidity, with <1 year predicted survival; or
(4) active infection during admission. Patients with late-
presentation ST-elevation MI, or stable angina, were not
included. Participants provided written, informed
consent prior to their inclusion in the study. Formal
assessment of capacity was performed where applicable;
all patients lacking the capacity to provide written,
informed consent were not approached to participate.
Patients were managed at the discretion of the operator.
If coronary angiography suggested a non-ACS final diag-
nosis, the patient was also excluded. Table 1 displays the
additional investigations performed, as per the ICON-1
study protocol. A 1-year follow-up clinical consultation
was performed.
The ICON-1 study was approved by the appropriate
Local Ethics Committee and National Research Ethics
Service (NRES; 12/NE/0160) and is compliant with the
principles outlined in the Declaration of Helsinki.
ICON-1 is registered with the United Kingdom Clinical
Research Network (UKCRN; ID 12742) and
ClinicalTrials.gov (NCT01933581). Data are presented
from the study recruitment period from February 2013
to December 2015.
Screening protocol
Patients fulfilling the study inclusion criteria, and
without exclusion criteria, were approached on arrival to
the ward. The study was explained in detail, verbally and
using a comprehensive written information sheet, and
the patient afforded the opportunity to ask questions.
The patient was given time to consider, before the
researcher returned to address any further questions
and obtain formal, written, informed consent. Patients
were given a minimum of 2 hours to consider participa-
tion; where possible, the patient was approached the
evening prior to angiography and provided informed
consent (where possible) the following morning. In
patients with visual impairment, the information sheet
and consent form were read in full. Patients unable to
consent, for example, due to language difficulties,
severe deafness, blindness or a lack of capacity, were not
recruited. Some patients requested that a family
member was present during the consent process, which
was accommodated. Details of all patients that under-
went screening, whether recruited or not were entered
into an anonymised screening log.
Statistical analysis
Continuous data are expressed in the form of mean±SD
and, where parametrically distributed, analysed using
unpaired Student’s t-test. Discrete variables were
expressed as numbers and percentages and analysed
using Pearson’s χ2 test or Fisher’s exact test if the contin-
gency table cell count was <5. The Statistical Package for
Social Sciences (SPSS) V.23.0 (SPSS, Chicago, Illinois,
USA) was used for all analyses.
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This study is reported in compliance with the
STrengthening the Reporting of OBservational studies
in Epidemiology (STROBE) statement.7
RESULTS
Patient characteristics
Of the 629 patients initially screened, 457 (72.7%) satis-
fied the a priori-defined eligibility criteria and were
approached to participate in ICON-1. The average age
of those screened was 81.2±4.8 years (mean±SD); 43.6%
were women. Of those approached, 319 (69.8%) pro-
vided informed consent and were recruited to ICON-1.
Following angiography, 18 patients were given non-ACS
final diagnoses, and 1 patient withdrawn their consent.
Accordingly, these patients were excluded from the
present study, giving a total of n=300 patients recruited.
The recruitment of the ICON-1 patient cohort is sum-
marised in figure 1. The characteristics of patients eli-
gible for recruitment were not significantly different
from the population screened. The final cohort
recruited did not differ significantly from the population
screened or eligible patients, with the exception of (1)
recruiting fewer female patients (39% of recruited
cohort vs 46.0% of eligible patients, p=0.033) and (2)
mode of presentation (eg, NSTEMI comprised 82.0% of
recruited cohort, cf. 76.1% of eligible patients; p<0.001).
Data demonstrate equivalent risk factor distributions in
the screened, eligible and recruited populations, with
the exception of family history of IHD (p<0.001). The
baseline characteristics of patients screened, as stratified
by recruitment status, are shown in table 2.
Study non-recruitment
In total, 59 eligible patients (13.5%) were unable to
provide informed consent to participate in ICON-1.
Most commonly, this was a result of the patient lacking
capacity to provide such informed consent (n=45;
76.3%), as assessed in accordance with the principles
outlined in the UK Mental Capacity Act (2005). The
remaining patients (n=14; 23.7%) were unable to
provide informed consent as a consequence of signifi-
cant language difficulties, severe deafness or blindness.
Those unable to provide informed consent were, on
average, older than those able to provide informed
consent (83.0±4.7 vs 81.0±4.7 years, p=0.002), but there
Table 1 Baseline characteristics, stratified by eligibility and recruitment status
All patients
screened
(A)
n=629
Eligible
patients
(B)
n=457
Recruited
patients (C)
n=300
Non-recruited
patients (D)
n=157
p Values for difference
between groups
A vs B B vs C C vs D
Female (%) 275 (43.7) 210 (46.0) 117 (39.0) 93 (59.2) 0.310 0.033* <0.001***
Age (years) 81.2±4.8 81.1±4.7 80.5±4.7 82.2±4.7 0.231 0.100 <0.001***
Presentation
NSTEMI (%) 458 (72.8) 348 (76.1) 246 (82.0) 105 (66.9)
UA (%) 86 (13.7) 67 (14.7) 51 (17.0) 19 (12.1) 0.032* <0.001*** <0.001***
Other (%) 85 (13.5) 38 (8.3) 3 (1.0) 33 (21.0)
Hypertension (%) 475 (75.5) 342 (74.8) 225 (75.0) 117 (74.5) 0.797 0.959 0.911
Diabetes (%) 162 (25.8) 112 (24.5) 70 (23.3) 42 (26.8) 0.640 0.712 0.420
Smoking status
Current smoker (%) 37 (5.9) 28 (6.1) 17 (5.7) 11 (7.0)
Ex-smoker (%) 377 (59.9) 251 (54.9) 162 (54.0) 89 (56.7) 0.242 0.914 0.648
Never smoked (%) 215 (34.2) 178 (38.9) 121 (40.3) 57 (36.3)
Hypercholesterolaemia (%) 358 (56.9) 264 (57.8) 180 (60.0) 84 (53.5) 0.779 0.541 0.181
Family history of IHD (%) 160 (25.4) 125 (27.4) 97 (32.3) 28 (17.8) 0.479 0.141 <0.001***
Renal impairment (%) 159 (25.3) 107 (23.4) 68 (22.7) 39 (24.8) 0.481 0.812 0.602
Previous MI (%) 221 (35.1) 147 (32.2) 95 (31.7) 52 (33.1) 0.308 0.885 0.651
Previous PCI (%) 138 (21.9) 95 (20.8) 61 (20.3) 34 (21.7) 0.648 0.880 0.741
Peripheral vascular disease (%) 63 (10.0) 42 (9.2) 28 (9.3) 14 (8.9) 0.649 0.947 0.883
Cerebrovascular disease (%) 80 (12.7) 57 (12.5) 44 (14.7) 13 (8.3) 0.904 0.489 0.065
Radial access (%) 549 (87.3) 411 (89.9) 268 (89.3) 143 (91.1) 0.178 0.790 0.555
Treatment
PCI (%) 456 (72.5) 349 (76.4) 251 (83.7) 98 (62.4)
CABG (%) 17 (2.7) 11 (2.4) 8 (2.7) 3 (1.9) 0.354 0.310 <0.001***
Medical management (%) 156 (24.8) 97 (21.2) 41 (13.7) 56 (35.7)
Number of stents in those
receiving PCI
1.7±1.3 1.7±1.2 1.8±1.1 1.6±1.4 0.932 0.534 0.142
Continuous variables are presented in the form of mean±SD, and discrete variables are presented in the form of n (%).
*Significant at p<0.05 level, **significant at p<0.01 level, ***significant at p<0.001 level.
CABG, coronary artery bypass surgery; IHD, ischaemic heart disease; MI, myocardial infarction; NSTEMI, non-ST-elevation myocardial
infarction; PCI, percutaneous coronary intervention; UA, unstable angina.
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was no difference between genders in the ability to
provide informed consent (13.5% of women were
unable to consent vs 12.0% of men, p=0.631).
Overall, 79 otherwise eligible patients (18.0%)
declined to participate in the study (table 3). The major-
ity of patients that declined did not offer a specific
reason for declining; 17.7% felt too anxious about the
coronary angiography and PCI procedure to consider
taking part in a study that entailed additional proce-
dures, and 15.2% did not wish to consider participate in
any research study. More women declined to participate
in the study compared with men (25.1% vs 10.0%,
p<0.001), as reflected in the lower number of women
recruited to the study overall. There was no significant
difference in age between those that declined and con-
sented (81.9±4.7 vs 81.5±4.7 years, p=0.571).
Patients aged 85 years and older
In total, 143 patients aged 85 years and older were
screened for inclusion; 102 (71.3%) were eligible to par-
ticipate. Of those eligible, 55 (53.9%) were successfully
enrolled in ICON-1. The oldest patient recruited was
93 years old. The greatest exclusion criterion in this sub-
group was significant valvular disease; 24 patients over
85 years old were ineligible to participate due to the
presence of concomitant moderate-to-severe valvular
pathology. A total of 24 patients were unable to provide
informed consent; 23 patients declined to participate.
DISCUSSION
Historically, the recruitment of older patients to clinical
research has represented a significant challenge. In the
present study, for the first time, we have demonstrated
that the majority of patients satisfying the study inclusion
criteria (69.8%) were successfully recruited to partici-
pate in the ICON-1 study, with a reciprocally low rate of
patients declining to participate (18.0%). Those who
declined were more likely to be women, and those
unable to provide informed consent (13.5%) were older
than those who could.
Despite a recent focus on the importance of recruiting
older people to cardiovascular research, the majority of
RCTs and observational studies fail to recruit older
patients with ACS, and a significant minority actively
exclude them. This leads to a continuing paucity of data
in this age group. Of the 44 RCTs in ACS reported in
2014, 10 studies (22.7%) had upper age limits (4 RCTs
excluded patients >75 years, 4 excluded >80 years, 1
excluded >85 years and 1 excluded >90 years). The
average age of participants across all RCTs was 62.0
±6.8 years. Only 2 RCTs (4.5%) specifically recruited
older patients.8 9 Of the 70 published prospective, obser-
vational studies, 11 (15.7%) had upper age limits
(1 study excluded >55 years, 3 excluded >75 years, 5
excluded >80 years and 2 excluded >85 years). The
average age of participants was 61.3±5.9 years. Two obser-
vational studies (2.9%) specifically recruited older
Figure 1 Flow diagram of
patients screened for inclusion in
ICON-1. ACS, acute coronary
syndrome; CABG, coronary artery
bypass graft; PCI, percutaneous
coronary intervention.
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patients.10 11 A systematic review of RCTs in ACS demon-
strated that the percentage of randomised trials exclud-
ing older patients appears to be falling, from 31.9% in
1996–2001 to 22.7% in 2014.5 Indeed, although enrol-
ment of older patients (≥75 years) has increased in
recent decades, only 10.3% of patients fell into this age
category in RCTs published between 1996 and 2000.5
The recruitment rate of older patients to ICON-1 com-
pares favourably to other observational, non-
cardiovascular studies in the older population, such as
the Newcastle 85+ study (71.7%).6 Despite recruiting
from a similar geographic area, the Newcastle 85+ study
enrolled patients using a community register and did
not approach patients in secondary care, undergoing
invasive investigations.
Several cardiovascular studies have exclusively
recruited older patients, with mixed success. The Italian
Elderly ACS study recruited a population comparable to
ICON-1, patients with non-ST-elevation ACS, aged ≥75
(mean 82) years.12 Patients were randomised to either
receive an early invasive or conservative management
strategy. Initially planning to recruit 504 patients, the
trial design was amended due to a slower-than-expected
recruitment rate. In total, 313 patients were recruited,
resulting in limited statistical power. The investigators
attributed slow recruitment to a number of factors,
including difficulty in obtaining informed consent and
significant comorbidity burden, making many patients
ineligible for recruitment due to exclusion criteria.
Recently, the After Eighty study recruited 457 patients,
aged ≥75 (mean 82) years, also evaluating conservative
versus invasive management of non-ST-elevation ACS.13
This study screened 1973 patients for inclusion, but only
23% were recruited. The authors credit the low recruit-
ment rate to logistical reasons and refusal to participate.
Thus, significant lessons should be learnt from these
trials, in order to better inform the design of future
studies, in the older population. Specifically, further
qualitative work is indicated to explore reasons for non-
participation and to design interventions that maximise
participation.
Our study is the first study to evaluate the recruitment
rate in detail among older patients presenting with ACS
(NSTEMI and UA) providing important insights into
the recruitment of such patients in future clinical
studies. In the UK, the set-up of the multicentre, the
British Heart Foundation SENIOR-RITA, trial is cur-
rently underway.14 Whether the beneficial effects of
revascularisation will be demonstrated in older patients
(≥75 years) with comorbidities presenting with NSTEMI
is unknown and will be investigated in SENIOR-RITA.
This is particularly important as this potentially frail
older cohort is becoming more prevalent. SENIOR-RITA
specifically aims to investigate these high-risk comorbid
frail older patients who are being denied advanced car-
diovascular care due to fear of complications and
Table 2 Investigations performed in the ICON-1 study
Investigation Performed Time taken
Blood tests 30 mL blood taken in cardiac catheterisation laboratory
and at 1 year follow-up
As part of routine care
Invasive imaging:
▸ Virtual histology intravascular ultrasound
▸ Optical coherence tomography
In cardiac catheterisation laboratory 15 min
Arterial stiffness Day 1 post-PCI 15 min
Endothelial function Day 1 post-PCI 15 min
Carotid intima media thickening Day 1 post-PCI 5 min
Transthoracic echocardiography Day 1 post-PCI 10 min
Frailty assessments:
▸ Fried criteria
▸ Rockwood criteria
Day 1 post-PCI and at 1 year follow-up 5 min
Quality of life questionnaire:
▸ EQ-5D
Day 1 post-PCI and at 1 year follow-up 15 min
Cognitive assessment:
▸ Montreal cognitive assessment
Day 1 post-PCI and at 1 year follow-up 10 min
PCI, percutaneous coronary intervention.
Table 3 Reasons for declining to participate
Reason
Number
(n=79)
No specific reason 26 (32.9%)
Anxiety about PCI procedure 14 (17.7%)
Not keen on taking part in any research 12 (15.2%)
Felt too unwell to consider study 8 (10.1%)
Concerned about distance from research
venue
7 (8.9%)
Worried about being carer for spouse 5 (6.3%)
Recent bereavement 3 (3.8%)
Already taken part in other research 3 (3.8%)
Needed to talk through with absent family
member
1 (1.3%)
PCI, percutaneous coronary intervention.
Sinclair H, Batty JA, Qiu W, et al. Open Heart 2016;3:e000436. doi:10.1136/openhrt-2016-000436 5
Interventional cardiology
group.bmj.com on September 15, 2016 - Published by http://openheart.bmj.com/Downloaded from 
perception of futility. We will include all-comer older
patients (≥75 years) with NSTEMI, including those with
comorbidities and those with cognitive impairment who
normally would be denied invasive care due to under-
lying comorbidity and in whom there is lack of evidence
currently in the management of NSTEMI.
Patients approached to participate in ICON-1 were
generally enthusiastic about participating in clinical
research, citing their altruistic wish to ‘give something
back’ and improve the treatment of patients presenting
in future. This contradicts previous evidence; one car-
diovascular RCT in patients aged 70–82 years found that
the primary reason for taking part in research was self-
interest (52.9%), access to ‘health checks’ or ‘peace of
mind’, followed by a sense of altruism (39.6%) to ‘help
research’ or ‘help others’.15 Indeed, several patients
recruited to ICON-1 mentioned the importance of as
few clinic visits as possible after initial recruitment,
citing a lack of transport. Seven patients cited distance
from the research venue as a reason for declining to par-
ticipate; previous research demonstrated inverse correl-
ation between the distance from the older patient’s
residence to the research venue, and the likelihood of
participation in a clinical trial.16
Several patients expressed anxiety regarding the
impending PCI procedure and felt unable to consider
additional procedures at that time. Care was taken by
the researchers to permit the patient adequate time to
assimilate the information given, often requiring mul-
tiple conversations with the patient (and their family,
where possible). Older patients who agree to participate
in research often take more time to make the decision
than those who decline,17 and patients who feel that
they have sufficient time to consider the information are
more likely to consent.18 This is time-consuming for the
research team and requires devoted researchers who are
able to develop sufficient rapport.
Guidance on ethical research in older people has sti-
pulated that studies should aim to recruit a majority of
women, in order to reflect the gender composition of
this population.19 However, women approached for par-
ticipation in ICON-1 were disproportionately more likely
to decline compared with men. Furthermore, the
present study demonstrated an anxiety among older
female patients regarding PCI, preventing them from
participating in the study. In addition, five female
patients declined to participate due to concerns that
taking part in research would affect their ability to care
for their spouse. Although a greater proportion of men
than women over the age of 75 years are unpaid carers,
this figure may be skewed as more women in this age
group are likely to be widowed.1 Indeed, three further
female patients in our cohort declined due to recent
bereavement. Thus, researchers must be sensitive to
such issues when approaching older and particularly
female patients for participation in clinical studies.
Patients unable to provide informed consent were, on
average, older than those able to provide consent. The
most frequent reason for being unable to provide
consent was a lack of capacity, secondary to cognitive
impairment (70%) either long-standing, or as a result of
a delirium state. Around 10% of the population aged
over 85 years have dementia;20 all research involving
older patients should take due consideration of mental
capacity and incorporate formal capacity assessment into
the process of informed consent. It is still possible to
recruit patients lacking mental capacity, while protecting
them from undue coercion, allowing the older patient
to participate and benefit from the advances brought
about by such research. In the UK, specific Research
Ethics Committees consider the involvement of patients
without capacity on an individual study basis.21
Given the evidence suggesting that older patients are
willing to participate in clinical research, is the poor his-
torical recruitment the fault of study investigators? In
one notable study of patients with breast cancer, investi-
gators approached 51% of patients aged <65 years com-
pared to only 35% of those aged ≥65 years (p=0.006).22
However, age was not a predictor of the patient provid-
ing informed consent (56% aged <65 years vs 50% aged
≥65 years, p=0.67).22 In not offering a trial to older
patients, physicians cited greater perceived therapeutic
toxicity (33%), unavailability of best-option treatment
(27%), unawareness of eligibility criteria (21%) and
incorrect suppositions of patient ineligibility (18%).22
A further study of over 1000 patients with breast cancer
demonstrated that investigators cited age as a factor in
opting not to discuss a trial in 17% of patients aged
≥65 years vs 3% of younger patients (p=0.04).23 A sig-
nificant change in attitudes towards involvement of
older patients in research is required if we are to see
substantial improvements in recruitment.
Recently, the PREDICT (increasing the PaRticipation
of the ElDerly In Clinical Trials) Consortium has com-
piled a charter for the rights of older patients in clinical
trials, aiming to narrow the gap between populations
recruited to clinical trials and real-world clinical prac-
tice.24 25 The charter outlines the following: (1) older
people have the right to access evidence-based treat-
ments, (2) clinical trials should be made as practicable
and safe as possible for older people, (3) outcome mea-
sures should be relevant for older people, (4) the values
of older people participating in clinical trials should be
respected and (5) the promotion of the inclusion of
older people in clinical trials to prevent discrimination.
Guidelines published by the Geriatric Working Party of
the European Forum for Good Clinical Practice suggest
that research should (1) actively recruit patients aged
over 75 years with no upper age limit, (2) recruit a
majority of women and (3) must justify exclusion
comorbidities in order to accurately reflect the popula-
tion studied.19
The extent to which the results of this study can be
generalised to all research in older people is limited by
the population studied in ICON-1. The study was an
observational cohort study rather than a RCT; the
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strategies employed to yield that high recruitment rate
observed may not be applicable to the latter.
Importantly, the population screened for recruitment
for ICON-1 had been selected; patients were only
referred for PCI from their district general hospitals if a
cardiologist had deemed them sufficiently fit. ICON-1
may therefore have recruited from a pool of patients
more robust and/or motivated than is representative of
the entire population of patients with non-ST-elevation
ACS and aged over 75 years. However, given the wide
case mix and large sample size, this cohort is representa-
tive of older patients receiving contemporary invasive
treatment for the management of ACS in the UK.
CONCLUSION
The recruitment rate of older patients to studies in ACS
remains low even in the contemporary era, resulting in a
paucity of data in this high-risk cohort. However, the
contribution of older patients must not be ignored, par-
ticularly in the setting of an ever-ageing population, in
whom cardiovascular disease burden is high. The
recruitment of older patients to the present study was
robust, comparing favourably to previous longitudinal
studies within this age group. Although enrolling older
people to research remains challenging and requires sig-
nificant adaptation from the inception of study design,
this cohort is generally enthusiastic to participate. By
taking the time to build rapport with the older patient,
identifying issues with consent, involving relatives in the
decision-making process and minimising the burden of
the study on the participant, researchers can ensure that
this valuable cohort of patients can contribute to our
understanding and management of cardiovascular
disease.
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